Moreover, Park and colleagues identified five plasma biomarker candidates via mass spectrometry (MS) based‐proteomic analysis and validated these performances for AD prediction using enzyme‐linked immunosorbent assay (ELISA), A2Macro, endoplasmic reticulum aminopeptidase 2 (ERAP2), vascular endothelial cadherin 5, angiotensin‐converting enzyme, galectin3‐binding protein (LGALS3BP), which were highly predictive of brain amyloid deposition with a high accuracy of 0.871(79% sensitivity, 84% specificity) in an independent validation cohort (n = 254).78 The gene discussed is ERAP2; the disease is Alzheimer disease.